US-based biotechnology firm Rocket Pharmaceuticals has announced the sale of a rare paediatric disease priority review voucher (PRV) for a substantial $180 million. The lucrative transaction provides a significant financial boost to the company, which specialises in gene therapies for rare diseases.
The priority review voucher was awarded to Rocket Pharmaceuticals by the US Food and Drug Administration (FDA) following the approval of their gene therapy, Kresladi (marnetegragene autotemcel), for the treatment of severe Leukocyte Adhesion Deficiency-I (LAD-I). LAD-I is a rare and life-threatening inherited immune disorder.
A priority review voucher is a transferable incentive designed to encourage the development of new drugs for rare paediatric diseases and certain tropical diseases. It allows the holder to expedite the FDA's review of a future drug application, shortening the standard 10-month review period to six months. This accelerated timeline can be invaluable for pharmaceutical companies, as it can bring new treatments to market quicker and potentially extend patent life, thereby increasing revenue generation.
The sale of this PRV for $180 million underscores the high value placed on these regulatory assets within the pharmaceutical industry. Such a significant cash infusion will enable Rocket Pharmaceuticals to further invest in its pipeline of gene therapies, which are often costly and time-consuming to develop. The company is currently working on treatments for other rare genetic disorders, and this capital will be crucial for advancing clinical trials and research efforts.
While the buyer of the PRV has not been publicly disclosed, such vouchers are typically acquired by larger pharmaceutical companies looking to accelerate the approval process for their own high-priority drug candidates. The transaction reflects a strategic move by Rocket Pharmaceuticals to monetise an asset derived from its successful drug development, providing immediate capital to fuel future innovation rather than holding the voucher for potential future use.
This sale highlights the ongoing innovation in the rare disease space and the mechanisms put in place by regulatory bodies to stimulate research in areas with unmet medical needs. For Rocket Pharmaceuticals, it represents a strong financial outcome and a clear path to continue their work in developing life-changing treatments.
Source: Rocket Pharmaceuticals